Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 14Neoplasm Metastasis 5Rectal Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Stomach Neoplasms 2Gallbladder Neoplasms 2Colonic Neoplasms 2Pancreatic Neoplasms 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Gastric Adenocarcinoma 1Digestive System Diseases 1Cholangiocarcinoma 1Carcinoma 1Bile Duct Neoplasms 1Advanced or Metastatic Solid Tumors 1Advanced Solid Tumors 1Adenocarcinoma 1

Interventions

Irinotecan 3pembrolizumab 2Oxaliplatin 2Leucovorin 2Fluorouracil 2trifluridine tipiracil drug combination 1pralsetinib 1napabucasin 1alectinib 1S-1 plus cisplatin 1Levoleucovorin 1KRN-330 1Indocyanine Green 1Imatinib Mesylate 1Fluorescein 1Docetaxel 1Cyclophosphamide 1Calcium Dobesilate 1Bupivacaine 1Bevacizumab 1Ascorbic Acid 15,10-methylenetetrahydrofolic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Gastrointestinal Diseases × trifluridine tipiracil drug combination × Clear all
NCT04457297 2026-01-21

ALTAIR

National Cancer Center Hospital East

Phase 3 Completed
243 enrolled 13 charts
Gastrointestinal

Digestive System Diseases, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡